Tweet

#ICYMI, at our inaugural R&D day we shared important updates across our pipeline, including our upcoming clinical plans for SRF617 and SRF388, as well as our newest development candidate, SRF813. #biotech #immunooncology
https://t.co/fM3qghiMa1